TMCnet News
Immuno-Oncology Deal Trends Report 2012-16 - Research and MarketsThe "Immuno-Oncology Deal Trends, 2012-16" report has been added to Research and Markets' offering. Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated. The Big Pharma and Mid Pharma peer sets are an integral part of development and have been furthering efforts via deal-making. The peer groups signed more than 300 immuno-oncology deals between 2012 and 2016, growing at a compound annual growth rate of 48%. Aggregate deal value over this period was $48bn. The majority of deals involved development of drugs for solid tumors, especially lung cancer and melanoma, and the target of choice was programmed death-ligand 1 (PD-L1). Bristol-Myers Squibb and Merck & Co led in transaction volume. More than 50% of the immuno-oncology deals between 2012 and 2016 involved testing combinations that may eventually address previously unresponsive patients and/or additional tumor types. Combination agreements are structured differently to traditional licensing deals and are often pre-competitive in nature, early stage, and involve only one or two single studies. There was nearly an even split in terms of how combinations were structured, with just over half consisting of an anti-cancer immunotherapy target with a non-immunotherapy target, and the rest consisting of two anti-cancer immunotherapies. Among the immuno-oncology targets, PD-L1 was most oten the backbone in the combination, and was paired up with vascular endothelial growth factor receptor or DNA synthesis or methylase inhibitors more often than with any other target. Throughout this report, the information on deals and trial collaborations is derived from three main sources:Medtrack, Strategic Transactions, and Trialtrove. Key Topics Covered: Executive Summary Immuno-Oncology: A Brief Introduction - Immuno-oncology has sparked multiple industry, academic, and government initiatives - Bibliography Key Trends in Immuno-Oncology Deal-Making - Immuno-oncology deal volume has rapidly increased - Bristol-Myers Squibb and Merck & Co were the top immuno-oncology dealmakers - Immuno-oncology represented most of the overall oncology deal value - Solid tumors, especially lung cancer and melanoma, led immuno-oncology deals - Non-Hodgkin's lymphoma and myeloma decreasing in overall share of deals - PD-L1/PD-1 dominated immuno-oncology deals - Immuno-oncology targets vary across indications - Bibliography Immuno-Oncology Combinations: Collaborative Efforts - Combinations are the driving force in immuno-oncology deal-making - Combination collaborations have unique characteristics - Combination collaborations - Bibliography Immuno-Oncology Deal-Making Case Studies - AstraZeneca has high hopes for durvalumab in combinations and in hematological cancers - Bristol-Myers Squibb deals with setbacks following early lead - Celgene is trying to make an impact in hematological cancers - GlaxoSmithKline looks to alternative immuno-oncology targets - Merck & Co gains key approvals for Keytruda - Merck KGaA and Pfizer get approval for fourth PD-L1 entrant Bavencio - Roche's Tecentriq gains the first approval among PD-L1 inhibitors in bladder cancer - Bibliography Appendix Companies Mentioned - AstraZeneca - Bristol-Myers Squibb - Celgene - Genentech - GlaxoSmithKline - Merck KGaA - Pfizer - Roche For more information about this report visit https://www.researchandmarkets.com/research/fg4pq4/immunooncology
View source version on businesswire.com: http://www.businesswire.com/news/home/20170720005794/en/ |
